Into the matrix: Targeting fibroblasts in pulmonary fibrosis

Current Opinion in Pulmonary Medicine

Volumn 18, Issue 5, 2012, Pages 462-469

  Sivakumar, Pitchumani ^a   Ntolios, Paschalis ^b   Jenkins, Gisli ^c   Laurent, Geoffrey ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

fibroblast; fibrosis; matrix; pathogenesis

Indexed keywords

ACETYLCYSTEINE; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; CARBON MONOXIDE; CORTICOSTEROID; CYTOKINE; FG 3019; GROWTH FACTOR; GS 6624; IW 001; LOSARTAN POTASSIUM; MITOGEN ACTIVATED PROTEIN KINASE; NINTEDANIB; OXYGEN; PIRFENIDONE; POMALIDOMIDE; PREDNISONE; PRM 151; QAX 576; RAPAMYCIN; RETINOIC ACID; RETINOID; RITUXIMAB; SMAD2 PROTEIN; SMAD3 PROTEIN; STAT6 PROTEIN; STX 100; TANZISERTIB; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BLOOD CLOTTING; CELL ACTIVATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; DRUG TARGETING; EFFECTOR CELL; EMPHYSEMA; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FIBROBLAST; GASTROESOPHAGEAL REFLUX; HUMAN; IMMUNOCOMPETENT CELL; INFECTION CONTROL; LUNG ALVEOLUS EPITHELIUM; LUNG ENDOTHELIUM; LUNG FIBROSIS; MACROPHAGE; MYOFIBROBLAST; NONHUMAN; OXYGEN THERAPY; PATIENT EDUCATION; PLASMAPHERESIS; PNEUMONIA; PROTEIN PHOSPHORYLATION; PULMONARY REHABILITATION; SIGNAL TRANSDUCTION; TH17 CELL; TH2 CELL; THROMBOCYTE;

CYTOKINES; EXTRACELLULAR MATRIX; FIBROBLASTS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MYOFIBROBLASTS; PULMONARY FIBROSIS; PYRIDONES; SIGNAL TRANSDUCTION;

EID: 84864866406     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328356800f     Document Type: Article

References (55)

1. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165:277-304.
2. Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174: 810-816. (Pubitemid 44511663)
3. Gribbin J, Hubbard RB, Le Jeune I, et al. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006; 61:980-985. (Pubitemid 44787169)
4. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788-824.
5. Selman M, Pardo A, Kaminski N. Idiopathic pulmonary fibrosis: aberrant recapitulation of developmental programs? PLoS Med 2008; 5:e62.
6. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134:136-151. (Pubitemid 32096342)
7. Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J 2007; 30:835-839. (Pubitemid 351194784)
8. Eickelberg O, Laurent GJ. The quest for the initial lesion in idiopathic pulmonary fibrosis: gene expression differences in IPF fibroblasts. Am J Respir Cell Mol Biol 2010; 42:1-2.
9. Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med 2011; 208:1339-1350.
10. Chapman HA. Epithelial-mesenchymal interactions in pulmonary fibrosis. Annu Rev Physiol 2011; 73:413-435.
11. Ekert JE, Murray LA, Das AM, et al. Chemokine (C-C motif) ligand 2 mediates direct and indirect fibrotic responses in human and murine cultured fibrocytes. Fibrogenesis Tissue Repair 2011; 4:23.
12. Moore BB, Murray L, Das A, et al. The role of CCL12 in the recruitment of fibrocytes and lung fibrosis. Am J Respir Cell Mol Biol 2006; 35:175-181. (Pubitemid 44175316)
13. Andersson-Sjoland A, de Alba CG, Nihlberg K, et al. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol 2008; 40:2129-2140.
14. Larsson O, Diebold D, Fan D, et al. Fibrotic myofibroblasts manifest genomewide derangements of translational control. PLoS One 2008; 3:e3220.
15. Emblom-Callahan MC, Chhina MK, Shlobin OA, et al., Genomic phenotype of noncultured pulmonary fibroblasts in idiopathic pulmonary fibrosis. Genomics 2010; 96:134-45.
16. Vuga LJ, Ben-Yehudah A, Kovkarova-Naumovski E, et al. WNT5A is a regulator of fibroblast proliferation and resistance to apoptosis. Am J Respir Cell Mol Biol 2009; 41:583-589.
17. Roberts AB, Tian F, Byfield SD, et al. Smad3 is key to TGF-beta-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis. Cytokine Growth Factor Rev 2006; 17 (1-2):19-27. (Pubitemid 43117513)
18. Hoyles RK, Derrett-Smith EC, Khan K, et al., An essential role for resident fibroblasts in experimental lung fibrosis is defined by lineage-specific deletion of high-affinity type II transforming growth factor beta receptor. Am J Respir Crit Care Med 2011; 183:249-261.
19. Wynn TA, Barron L. Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis 2010; 30:245-257.
20. Murray LA, Chen Q, Kramer MS, et al. TGF-beta driven lung fibrosis is macrophage dependent and blocked by serum amyloid P. Int J Biochem Cell Biol 2011; 43:154-162.
21. Kono M, Nakamura Y, Suda T, et al. Plasma CCN2 (connective tissue growth factor; CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF). Clin Chim Acta 2011; 412 (23-24):2211-2215.
22. Konigshoff M, Balsara N, Pfaff EM, et al. Functional Wnt signaling is increased in idiopathic pulmonary fibrosis. PLoS One 2008; 3:e2142.
23. Henderson WR Jr, Chi EY, Ye X, et al. Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci U S A 2010; 107:14309-14314.
24. Fonseca C, Abraham D, Renzoni EA. Endothelin in pulmonary fibrosis. Am J Respir Cell Mol Biol 2011; 44:1-10.
25. Swigris JJ, Brown KK. The role of endothelin-1 in the pathogenesis of idiopathic pulmonary fibrosis. BioDrugs 2010; 24:49-54.
26. Schroll S, Arzt M, Sebah D, et al. Improvement of bleomycin-induced pulmonary hypertension and pulmonary fibrosis by the endothelin receptor antagonist bosentan. Respir Physiol Neurobiol 2010; 170:32-36.
27. Raja SG.Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis Curr Opin Investig Drugs 2010 11 1066-1073.
28. Deng X, Mercer PF, Scotton CJ, et al. Thrombin induces fibroblast CCL2/JE production and release via coupling of PAR1 to Galphaq and cooperation between ERK1/2 and Rho kinase signaling pathways. Mol Biol Cell 2008; 19:2520-2533.
29. Chambers RC. Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? Br J Pharmacol 2008; 153 (Suppl 1):S367-S378. (Pubitemid 351340998)
30. Tager AM, LaCamera P, Shea BS, et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 2008; 14:45-54.
31. Xu MY, Porte J, Knox AJ, et al. Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q). Am J Pathol 2009; 174: 1264-1279.
32. Mi S, Li Z, Yang HZ, et al. Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-beta1-dependent and -independent mechanisms. J Immunol 2011; 187:3003-3014.
33. Gilani SR, Vuga LJ, Lindell KO, et al. CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis. PLoS One 2010; 5:e8959.
34. Lo Re S, Lecocq M, Uwambayinema F, et al. Platelet-derived growth factorproducing CD4 Foxp3 regulatory T lymphocytes promote lung fibrosis. Am J Respir Crit Care Med 2011; 184:1270-1281.
35. Barron L, Wynn TA. Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages. Am J Physiol Gastrointest Liver Physiol 2011; 300:G723-G728.
36. Wight TN, Potter-Perigo S. The extracellular matrix: an active or passive player in fibrosis? Am J Physiol Gastrointest Liver Physiol 2011; 301:G950-G955.
37. Laurent GJ, Chambers RC, Hill MR, McAnulty RJ. Regulation of matrix turnover: fibroblasts, forces, factors and fibrosis. Biochem Soc Trans 2007; 35 (Pt 4):647-651. (Pubitemid 47310332)
38. Kliment CR, Oury TD. Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis. Free Radic Biol Med 2010; 49:707-717.
39. Manni ML, Czajka CA, Oury TD, Gilbert TW. Extracellular matrix powder protects against bleomycin-induced pulmonary fibrosis. Tissue Eng Part A 2011; 17:2795-2804.
40. Datta A, Scotton CJ, Chambers RC. Novel therapeutic approaches for pulmonary fibrosis. Br J Pharmacol 2011; 163:141-172.
41. Moodley YP, Caterina P, Scaffidi AK, et al. Comparison of the morphological and biochemical changes in normal human lung fibroblasts and fibroblasts derived from lungs of patients with idiopathic pulmonary fibrosis during FasLinduced apoptosis. J Pathol 2004; 202:486-495. (Pubitemid 38456167)
42. Xia H, Khalil W, Kahm J, et al. Pathologic caveolin-1 regulation of PTEN in idiopathic pulmonary fibrosis. Am J Pathol 2010; 176:2626-2637.
43. Chen D, Carpenter A, Abrahams J, et al. Protease-activated receptor 1 activation is necessary for monocyte chemoattractant protein 1-dependent leukocyte recruitment in vivo. J Exp Med 2008; 205:1739-1746.
44. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353:2229-2242. (Pubitemid 41697286)
45. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377:1760-1769.
46. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365:1079-1087.
47. Ortiz LA, Gambelli F, McBride C, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A 2003; 100:8407-8411. (Pubitemid 36842558)
48. Germano D, Blyszczuk P, Valaperti A, et al. Prominin-1/CD133 lung epithelial progenitors protect from bleomycin-induced pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179:939-949.
49. Tzouvelekis A, Koliakos G, Ntolios P, et al. Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal. J Transl Med 2011; 9:182.
50. Hind M, Maden M. Retinoic acid induces alveolar regeneration in the adult mouse lung. Eur Respir J 2004; 23:20-27. (Pubitemid 38088491)
51. Massaro GD, Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat Med 1997; 3:675-677. (Pubitemid 27264979)
52. Stinchcombe SV, Maden M. Retinoic acid induced alveolar regeneration: critical differences in strain sensitivity. Am J Respir Cell Mol Biol 2008; 38:185-191. (Pubitemid 351162840)
53. Massaro GD, Massaro D. Retinoic acid treatment partially rescues failed septation in rats and in mice. Am J Physiol Lung Cell Mol Physiol 2000; 278:L955-L960. (Pubitemid 30351050)
54. Stolk J, Stockley RA, Stoel BC, et al., Randomized controlled trial for emphysema with a selective agonist of the gamma type retinoic acid receptor. Eur Respir J 2012. [Epub ahead of print].
55. Stolk J, Cooper BG, Stoel B, et al. Retinoid treatment of Emphysema in Patients on the Alpha-1 International Registry. The REPAIR study: study design, methodology and quality control of study assessments. Ther Adv Respir Dis 2010; 4:319-332.